MEI Pharma, Inc. (MEIP)
- Previous Close
3.2500 - Open
3.2500 - Bid --
- Ask --
- Day's Range
3.2328 - 3.3700 - 52 Week Range
3.2000 - 7.9700 - Volume
6,477 - Avg. Volume
21,800 - Market Cap (intraday)
22.454M - Beta (5Y Monthly) 0.64
- PE Ratio (TTM)
1.13 - EPS (TTM)
2.9800 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 16, 2023
- 1y Target Est
23.00
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
www.meipharma.comRecent News: MEIP
Performance Overview: MEIP
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEIP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEIP
Valuation Measures
Market Cap
22.45M
Enterprise Value
-25.00M
Trailing P/E
1.13
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.31
Price/Book (mrq)
0.38
Enterprise Value/Revenue
-0.34
Enterprise Value/EBITDA
-1.54
Financial Highlights
Profitability and Income Statement
Profit Margin
27.31%
Return on Assets (ttm)
8.30%
Return on Equity (ttm)
36.79%
Revenue (ttm)
72.65M
Net Income Avi to Common (ttm)
19.84M
Diluted EPS (ttm)
2.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
59.48M
Total Debt/Equity (mrq)
20.22%
Levered Free Cash Flow (ttm)
433.62k